Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Gastrointestinal Surgery
Published in: Journal of Gastrointestinal Surgery 7/2013

01-07-2013 | 2012 SSAT Plenary Presentation

Vein Involvement During Pancreaticoduodenectomy: Is There a Need for Redefinition of “Borderline Resectable Disease”?

Authors: Kaitlyn J. Kelly, Emily Winslow, David Kooby, Neha L. Lad, Alexander A. Parikh, Charles R. Scoggins, Syed Ahmad, Robert C. Martin, Shishir K. Maithel, H. J. Kim, Nipun B. Merchant, Clifford S. Cho, Sharon M. Weber

Published in: Journal of Gastrointestinal Surgery | Issue 7/2013

Login to get access

Abstract

Introduction

Current National Comprehensive Cancer Network guidelines recommend neoadjuvant therapy for borderline resectable pancreatic adenocarcinoma to increase the likelihood of achieving R0 resection. A consensus has not been reached on the degree of venous involvement that constitutes borderline resectability. This study compares the outcome of patients who underwent pancreaticoduodenectomy with or without vein resection without neoadjuvant therapy.

Methods

A multi-institutional database of patients who underwent pancreaticoduodenectomy was reviewed. Patients who required vein resection due to gross vein involvement by tumor were compared to those without evidence of vein involvement.

Results

Of 492 patients undergoing pancreaticoduodenectomy, 70 (14 %) had vein resection and 422 (86 %) did not. There was no difference in R0 resection (66 vs. 75 %, p = NS). On multivariate analysis, vein involvement was not predictive of disease-free or overall survival.

Conclusion

This is the largest modern series examining patients with or without isolated vein involvement by pancreas cancer, none of whom received neoadjuvant therapy. Oncological outcome was not different between the two groups. These data suggest that up-front surgical resection is an appropriate option and call into question the inclusion of isolated vein involvement in the definition of “borderline resectable disease.”
Literature
1.
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., and Thun, M.J., Cancer statistics, 2008. CA Cancer J Clin 2008; 58(2): 71–96.PubMedCrossRef
2.
Neoptolemos, J.P., Stocken, D.D., Friess, H., Bassi, C., Dunn, J.A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., Falconi, M., Pederzoli, P., Pap, A., Spooner, D., Kerr, D.J., and Buchler, M.W., A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350(12): 1200–10.PubMedCrossRef
3.
Neoptolemos, J.P., Stocken, D.D., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D., Padbury, R., Moore, M.J., Gallinger, S., Mariette, C., Wente, M.N., Izbicki, J.R., Friess, H., Lerch, M.M., Dervenis, C., Olah, A., Butturini, G., Doi, R., Lind, P.A., Smith, D., Valle, J.W., Palmer, D.H., Buckels, J.A., Thompson, J., McKay, C.J., Rawcliffe, C.L., and Buchler, M.W., Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304(10): 1073–81.PubMedCrossRef
4.
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., Gutberlet, K., Kettner, E., Schmalenberg, H., Weigang-Koehler, K., Bechstein, W.O., Niedergethmann, M., Schmidt-Wolf, I., Roll, L., Doerken, B., and Riess, H., Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297(3): 267–77.PubMedCrossRef
5.
Regine, W.F., Winter, K.A., Abrams, R., Safran, H., Hoffman, J.P., Konski, A., Benson, A.B., Macdonald, J.S., Rich, T.A., and Willett, C.G., Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 2011; 18(5): 1319–26.PubMedCrossRef
6.
Assifi, M.M., Lu, X., Eibl, G., Reber, H.A., Li, G., and Hines, O.J., Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 2011; 150(3): 466–73.PubMedCrossRef
7.
Andriulli, A., Festa, V., Botteri, E., Valvano, M.R., Koch, M., Bassi, C., Maisonneuve, P., and Sebastiano, P.D., Neoadjuvant/Preoperative Gemcitabine for Patients with Localized Pancreatic Cancer: A Meta-analysis of Prospective Studies. Ann Surg Oncol 2012; 19(5): 1644–62.PubMedCrossRef
8.
Heinrich, S., Pestalozzi, B., Lesurtel, M., Berrevoet, F., Laurent, S., Delpero, J.R., Raoul, J.L., Bachellier, P., Dufour, P., Moehler, M., Weber, A., Lang, H., Rogiers, X., and Clavien, P.A., Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer 2011; 11: 346.PubMedCrossRef
9.
Varadhachary, G.R., Tamm, E.P., Abbruzzese, J.L., Xiong, H.Q., Crane, C.H., Wang, H., Lee, J.E., Pisters, P.W., Evans, D.B., and Wolff, R.A., Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006; 13(8): 1035–46.PubMedCrossRef
10.
Callery, M.P., Chang, K.J., Fishman, E.K., Talamonti, M.S., William Traverso, L., and Linehan, D.C., Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009; 16(7): 1727–33.PubMedCrossRef
11.
Chun, Y.S., Milestone, B.N., Watson, J.C., Cohen, S.J., Burtness, B., Engstrom, P.F., Haluszka, O., Tokar, J.L., Hall, M.J., Denlinger, C.S., Astsaturov, I., and Hoffman, J.P., Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol 2010; 17(11): 2832–8.PubMedCrossRef
12.
Porembka, M.R., Hawkins, W.G., Linehan, D.C., Gao, F., Ma, C., Brunt, E.M., and Strasberg, S.M., Radiologic and intraoperative detection of need for mesenteric vein resection in patients with adenocarcinoma of the head of the pancreas. HPB (Oxford) 2011; 13(9): 633–42.CrossRef
13.
Clavien, P.A., Sanabria, J.R., and Strasberg, S.M., Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery 1992; 111(5): 518–26.PubMed
14.
Dindo, D., Demartines, N., and Clavien, P.A., Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240(2): p. 205–13.PubMedCrossRef
15.
Weber, S.M., Cho, C.S., Merchant, N., Pinchot, S., Rettammel, R., Nakeeb, A., Bentrem, D., Parikh, A., Mazo, A.E., Martin, R.C., 3rd, Scoggins, C.R., Ahmad, S.A., Kim, H.J., Hamilton, N., Hawkins, W., Max Schmidt, C., and Kooby, D.A., Laparoscopic left pancreatectomy: complication risk score correlates with morbidity and risk for pancreatic fistula. Ann Surg Oncol 2009; 16(10): 2825–33.PubMedCrossRef
16.
Bachellier, P., Nakano, H., Oussoultzoglou, P.D., Weber, J.C., Boudjema, K., Wolf, P.D., and Jaeck, D., Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile? Am J Surg, 2001. 182(2): 120–9.PubMedCrossRef
17.
Howard, T.J., Villanustre, N., Moore, S.A., DeWitt, J., LeBlanc, J., Maglinte, D., and McHenry, L., Efficacy of venous reconstruction in patients with adenocarcinoma of the pancreatic head. J Gastrointest Surg 2003; 7(8): 1089–95.PubMedCrossRef
18.
Kaneoka, Y., Yamaguchi, A., and Isogai, M., Portal or superior mesenteric vein resection for pancreatic head adenocarcinoma: prognostic value of the length of venous resection. Surgery 2009; 145(4): 417–25.PubMedCrossRef
19.
Kawada, M., Kondo, S., Okushiba, S., Morikawa, T., and Katoh, H., Reevaluation of the indications for radical pancreatectomy to treat pancreatic carcinoma: is portal vein infiltration a contraindication? Surg Today 2002; 32(7): 598–601.PubMedCrossRef
20.
Poon, R.T., Fan, S.T., Lo, C.M., Liu, C.L., Lam, C.M., Yuen, W.K., Yeung, C., and Wong, J., Pancreaticoduodenectomy with en bloc portal vein resection for pancreatic carcinoma with suspected portal vein involvement. World J Surg 2004; 28(6): 602–8.PubMedCrossRef
21.
Riediger, H., Makowiec, F., Fischer, E., Adam, U., and Hopt, U.T., Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J Gastrointest Surg 2006; 10(8): 1106–15.PubMedCrossRef
22.
Shimada, K., Sano, T., Sakamoto, Y., and Kosuge, T., Clinical implications of combined portal vein resection as a palliative procedure in patients undergoing pancreaticoduodenectomy for pancreatic head carcinoma. Ann Surg Oncol 2006; 13(12): 1569–78.PubMedCrossRef
23.
Tseng, J.F., Raut, C.P., Lee, J.E., Pisters, P.W., Vauthey, J.N., Abdalla, E.K., Gomez, H.F., Sun, C.C., Crane, C.H., Wolff, R.A., and Evans, D.B., Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004; 8(8): 935–49; discussion 949–50.PubMedCrossRef
24.
Turley, R.S., Peterson, K., Barbas, A.S., Ceppa, E.P., Paulson, E.K., Blazer, D.G., 3rd, Clary, B.M., Pappas, T.N., Tyler, D.S., McCann, R.L., and White, R.R., Vascular Surgery Collaboration During Pancreaticoduodenectomy With Vascular Reconstruction. Ann Vasc Surg 2012; 26(5):685–92.PubMedCrossRef
25.
Wang, J., Estrella, J.S., Peng, L., Rashid, A., Varadhachary, G.R., Wang, H., Lee, J.E., Pisters, P.W., Vauthey, J.N., Katz, M.H., Gomez, H.F., Evans, D.B., Abbruzzese, J.L., and Fleming, J.B., Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 2011; 118(15):3801–11.PubMedCrossRef
26.
Yekebas, E.F., Bogoevski, D., Cataldegirmen, G., Kunze, C., Marx, A., Vashist, Y.K., Schurr, P.G., Liebl, L., Thieltges, S., Gawad, K.A., Schneider, C., and Izbicki, J.R., En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients. Ann Surg 2008; 247(2): 300–9.PubMedCrossRef
27.
Pancreatic adenocarcinoma. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology 2012.
28.
Abrams, R.A., Lowy, A.M., O'Reilly, E.M., Wolff, R.A., Picozzi, V.J., and Pisters, P.W., Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 2009; 16(7): 1751–6.PubMedCrossRef
29.
Jain, S., Sacchi, M., Vrachnos, P., and Lygidakis, N.J., Carcinoma of the pancreas with portal vein involvement--our experience with a modified technique of resection. Hepatogastroenterology 2005; 52(65): 1596–600.PubMed
30.
Muller, S.A., Hartel, M., Mehrabi, A., Welsch, T., Martin, D.J., Hinz, U., Schmied, B.M., and Buchler, M.W., Vascular resection in pancreatic cancer surgery: survival determinants. J Gastrointest Surg 2009; 13(4): 784–92.PubMedCrossRef
31.
Martin, R.C., 2nd, Scoggins, C.R., Egnatashvili, V., Staley, C.A., McMasters, K.M., and Kooby, D.A., Arterial and venous resection for pancreatic adenocarcinoma: operative and long-term outcomes. Arch Surg 2009; 144(2): 154–9.PubMedCrossRef
32.
Nagai, S., Fujii, T., Kodera, Y., Kanda, M., Sahin, T.T., Kanzaki, A., Yamada, S., Sugimoto, H., Nomoto, S., Takeda, S., Morita, S., and Nakao, A., Impact of operative blood loss on survival in invasive ductal adenocarcinoma of the pancreas. Pancreas 2011; 40(1): 3–9.PubMedCrossRef
33.
Raut, C.P., Tseng, J.F., Sun, C.C., Wang, H., Wolff, R.A., Crane, C.H., Hwang, R., Vauthey, J.N., Abdalla, E.K., Lee, J.E., Pisters, P.W., and Evans, D.B., Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007; 246(1): 52–60.PubMedCrossRef
34.
Sohn, T.A., Yeo, C.J., Cameron, J.L., Koniaris, L., Kaushal, S., Abrams, R.A., Sauter, P.K., Coleman, J., Hruban, R.H., and Lillemoe, K.D., Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4(6): 567–79.PubMedCrossRef
35.
Kazanjian, K.K., Hines, O.J., Duffy, J.P., Yoon, D.Y., Cortina, G., and Reber, H.A., Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg 2008; 143(12): 1166–71.PubMedCrossRef
36.
Ramacciato, G., Mercantini, P., Petrucciani, N., Giaccaglia, V., Nigri, G., Ravaioli, M., Cescon, M., Cucchetti, A., and Del Gaudio, M., Does portal-superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma? Ann Surg Oncol 2009; 16(4): 817–25.PubMedCrossRef
37.
Nakagohri, T., Kinoshita, T., Konishi, M., Inoue, K., and Takahashi, S., Survival benefits of portal vein resection for pancreatic cancer. Am J Surg 2003; 186(2): 149–53.PubMedCrossRef
38.
Kurosaki, I., Hatakeyama, K., Minagawa, M., and Sato, D., Portal vein resection in surgery for cancer of biliary tract and pancreas: special reference to the relationship between the surgical outcome and site of primary tumor. J Gastrointest Surg 2008; 12(5): 907–18.PubMedCrossRef
39.
Shibata, C., Kobari, M., Tsuchiya, T., Arai, K., Anzai, R., Takahashi, M., Uzuki, M., Sawai, T., and Yamazaki, T., Pancreatectomy combined with superior mesenteric-portal vein resection for adenocarcinoma in pancreas. World J Surg 2001; 25(8): 1002–5.PubMedCrossRef
40.
Capussotti, L., Massucco, P., Ribero, D., Vigano, L., Muratore, A., and Calgaro, M., Extended lymphadenectomy and vein resection for pancreatic head cancer: outcomes and implications for therapy. Arch Surg 2003; 138(12): 1316–22.PubMedCrossRef
41.
Zhou, G.W., Wu, W.D., Xiao, W.D., Li, H.W., and Peng, C.H., Pancreatectomy combined with superior mesenteric-portal vein resection: report of 32 cases. Hepatobiliary Pancreat Dis Int 2005; 4(1): 130–4.PubMed
42.
Al-Haddad, M., Martin, J.K., Nguyen, J., Pungpapong, S., Raimondo, M., Woodward, T., Kim, G., Noh, K., and Wallace, M.B., Vascular resection and reconstruction for pancreatic malignancy: a single center survival study. J Gastrointest Surg 2007; 11(9): 1168–74.PubMedCrossRef
Metadata
Title
Vein Involvement During Pancreaticoduodenectomy: Is There a Need for Redefinition of “Borderline Resectable Disease”?
Authors
Kaitlyn J. Kelly
Emily Winslow
David Kooby
Neha L. Lad
Alexander A. Parikh
Charles R. Scoggins
Syed Ahmad
Robert C. Martin
Shishir K. Maithel
H. J. Kim
Nipun B. Merchant
Clifford S. Cho
Sharon M. Weber
Publication date
01-07-2013
Publisher
Springer-Verlag
Published in
Journal of Gastrointestinal Surgery / Issue 7/2013
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-013-2178-5

Other articles of this Issue 7/2013

Journal of Gastrointestinal Surgery 7/2013 Go to the issue

Original Article

Improved Long-Term Survival After Esophagectomy for Esophageal Cancer: Influence of Epidemiologic Shift and Neoadjuvant Therapy

Original Article

Changes of T Cells and Cytokines TGF-β1 and IL-10 in Mice During Liver Metastasis of Colon Carcinoma: Implications for Liver Anti-tumor Immunity

Original Article

Outcomes for Trainees vs Experienced Surgeons Undertaking Laparoscopic Antireflux Surgery - Is Equipoise Achieved?

Case Report

Acinar Cell Cystadenoma of the Pancreas: Report of Three Cases and Literature Review

Original Article

Cadmium Exposure and Liver Disease among US Adults

Original Article

Pancreatic Arteriovenous Malformation